Zhejiang Beta’s Conmana, a Cancer Drug, is a Big Winner
publication date: Aug 23, 2013
In 2011, Zhejiang Beta received CFDA approval for Conmana (icotinib), an oral EGFR tyrosine kinase inhibitor that is indicated as a treatment for non-small cell lung cancer. Conmana is a me-too drug, and its clinical trial results were more or less in line with first-gen members of the class. However, its development costs ($20-$30 million) were only a small fraction of its big pharma competitors (up to $1 billion), and development time, from start to finish, was a short eight years.As a result, Zhejiang Beta can offer its drug at a price that undercuts the cost of its big pharma competition by 33%. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.